Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2019

01-07-2019 | Endoscopic Retrograde Pancreatography | Pancreatic Tumors

Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma

Authors: So Nakamura, MD, Yoshihiko Sadakari, MD, PhD, Takao Ohtsuka, MD, PhD, Takafumi Okayama, MD, Yohei Nakashima, MD, Yoshitaka Gotoh, MD, Kiyoshi Saeki, MD, Yasuhisa Mori, MD, PhD, Kohei Nakata, MD, PhD, Yoshihiro Miyasaka, MD, PhD, Hideya Onishi, MD, PhD, Yoshinao Oda, MD, PhD, Michael Goggins, MB, MD, Masafumi Nakamura, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 7/2019

Login to get access

Abstract

Background

Pancreatic ductal adenocarcinoma (PDAC) is a lethal neoplasm because of difficulties in early detection. Several studies have recently suggested that exosomes may have potential as novel biomarkers. This study aimed to isolate exosomes from pancreatic juice and to investigate whether exosomal microRNAs (ex-miRs) could be used as biomarkers for PDAC.

Methods

Pancreatic juice was collected from patients with PDAC and chronic pancreatitis (CP) by endoscopic retrograde pancreatography. Exosomes were extracted by ultracentrifugation. The presence of exosomes was confirmed by electron microscopy and Western blotting using anti-CD63, -CD81, and -TSG101 antibodies. Relative levels of ex-miR-21 and ex-miR-155 were quantified and compared between PDAC and CP patients.

Results

A total of 35 pancreatic juice samples (27 PDAC and 8 CP) were collected. Relative levels of both ex-miR-21 and ex-miR-155 were significantly higher in PDAC patients compared with CP patients (p < 0.001 and p = 0.008, respectively). By contrast, no significant difference was apparent in relative levels of miR-21 and miR-155 in whole pancreatic juice from PDAC patients compared with CP patients (p = 0.08 and p = 0.61, respectively). Ex-miR-21 and ex-miR-155 levels discriminated PDAC patients from CP patients with area under the curve values of 0.90 and 0.89, respectively. The accuracies of ex-miR-21 levels, ex-miR-155 levels, and pancreatic juice cytology were 83%, 89%, and 74%, respectively. When combining the results of ex-miR profiling with pancreatic juice cytology, the accuracy was improved to 91%.

Conclusions

We successfully extracted exosomes from pancreatic juice. Ex-miRs, including ex-miR-21 and ex-miR-155, in pancreatic juice may be developed as biomarkers for PDAC.
Appendix
Available only for authorised users
Literature
1.
2.
Ahmed K, Sussman JJ, Wang J, et al. A case of EUS-guided FNA-related pancreatic cancer metastasis to the stomach. Gastrointest Endosc 2011;74:231–3.CrossRefPubMed
3.
Chong A, Venugopal K, Segarajasingam D, et al. Tumor seeding after EUS-guided FNA of pancreatic tail neoplasia. Gastrointest Endosc 2011;74:933–5.CrossRefPubMed
4.
Kanno A, Masamune A, Hanada K, et al. Multicenter study of early pancreatic cancer in Japan. Pancreatology 2018;18:61–67.CrossRefPubMed
5.
Kimura H, Ohtsuka T, Matsunaga T, et al. Predictors and diagnostic strategies for early-stage pancreatic ductal adenocarcinoma: a retrospective study. Pancreas 2015;44:1148–54.CrossRefPubMed
6.
Ohtsuka T, Tamura K, Ideno N, et al. Role of ERCP in the era of EUS-FNA for preoperative cytological confirmation of resectable pancreatic ductal adenocarcinoma. Surg Today 2014;44:1887–92.CrossRefPubMed
7.
8.
Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997–1006.CrossRefPubMed
9.
Xu J, Cao Z, Liu W, et al. Plasma miRNAs Effectively distinguish patients with pancreatic cancer from controls: a multicenter study. Ann Surg 2016;263:1173-9.CrossRefPubMed
10.
Li A, Yu J, Kim H, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 2013;19:3600–10.CrossRefPubMedPubMedCentral
11.
Abue M, Yokoyama M, Shibuya R, et al. Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol 2015;46:539–47.CrossRefPubMed
12.
Schultz NA, Dehlendorff C, Jensen BV, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA 2014;311:392–404.CrossRefPubMed
13.
Silverman JM, Reiner NE. Exosomes and other microvesicles in infection biology: organelles with unanticipated phenotypes. Cell Microbiol 2011;13:1–9.CrossRefPubMed
14.
Que R, Ding G, Chen J, et al. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J Surg Oncol 2013;11:219.CrossRefPubMedPubMedCentral
15.
Madhavan B, Yue S, Galli U, et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer 2015;136:2616–27.CrossRefPubMed
16.
Xu YF, Hannafon BN, Zhao YD, et al. Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer. Oncotarget 2017;8:77028–77040.PubMedPubMedCentral
17.
Mikamori M, Yamada D, Eguchi H, et al. MicroRNA-155 controls exosome synthesis and promotes gemcitabine resistance in pancreatic ductal adenocarcinoma. Sci Rep 2017;7:42339.CrossRefPubMedPubMedCentral
18.
Lai X, Wang M, McElyea SD, et al. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett 2017;393:86–93.CrossRefPubMedPubMedCentral
19.
Takahasi K, Iinuma H, Wada K, et al. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci 2018;25:155–161.CrossRefPubMed
20.
Goto T, Fujiya M, Konishi H, et al. An elevated expression of serum exosomal microRNA-191, -21, -451a of pancreatic neoplasm is considered to be efficient diagnostic marker. BMC Cancer 2018;18:116.CrossRefPubMedPubMedCentral
21.
Sadakari Y, Ohtsuka T, Ohuchida K, et al. MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. JOP 2010;11:587–92.PubMed
22.
Costa-Silva B, Aiello NM, Ocean AJ, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol 2015;17:816–26.CrossRefPubMedPubMedCentral
23.
Li L, Masica D, Ishida M, et al. Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology 2014;60:896–907.CrossRefPubMed
24.
Lotvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 2014;3:26913.CrossRefPubMed
25.
Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009;2:807–13.CrossRef
26.
Zheng J, Hernandez JM, Doussot A, et al. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancreatic cancer. HPB (Oxford) 2018;20(7):597–604.CrossRef
27.
Severino V, Dumonceau JM, Delhaye M, et al. Extracellular vesicles in bile as markers of malignant biliary stenoses. Gastroenterology 2017;153:495–504.e8.
28.
Pan X, Wang ZX, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2010;10:1224–32.CrossRefPubMed
29.
Gironella M, Seux M, Xie MJ, et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci USA 2007;104:16170–5.CrossRefPubMedPubMedCentral
30.
Suenaga M, Sadakari Y, Almario JA, et al. Using an endoscopic distal cap to collect pancreatic fluid from the ampulla (with video). Gastrointest Endosc 2017;86:1152–1156.e2.
31.
Yu J, Sadakari Y, Shindo K, et al. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut 2017;66:1677–1687.CrossRefPubMed
32.
Suenaga M, Yu J, Shindo K, et al. Pancreatic juice mutation concentrations can help predict the grade of dysplasia in patients undergoing pancreatic surveillance. Clin Cancer Res 2018;24(12):2963–2974.CrossRefPubMedPubMedCentral
Metadata
Title
Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma
Authors
So Nakamura, MD
Yoshihiko Sadakari, MD, PhD
Takao Ohtsuka, MD, PhD
Takafumi Okayama, MD
Yohei Nakashima, MD
Yoshitaka Gotoh, MD
Kiyoshi Saeki, MD
Yasuhisa Mori, MD, PhD
Kohei Nakata, MD, PhD
Yoshihiro Miyasaka, MD, PhD
Hideya Onishi, MD, PhD
Yoshinao Oda, MD, PhD
Michael Goggins, MB, MD
Masafumi Nakamura, MD, PhD, FACS
Publication date
01-07-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 7/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07269-z

Other articles of this Issue 7/2019

Annals of Surgical Oncology 7/2019 Go to the issue

Gastrointestinal Oncology

Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study

Thoracic Oncology

Survival Benefit of Left Lower Paratracheal (4L) Lymph Node Dissection for Patients with Left-Sided Non-small Cell Lung Cancer: Once Neglected But of Great Importance

Thoracic Oncology

A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer

Breast Oncology

The SERM Saga, Something from Nothing: American Cancer Society/SSO Basic Science Lecture

Thoracic Oncology

Better Survival After 4L Lymph Node Dissection for Early-Stage, Left-Sided, Non-small Cell Lung Cancer: Are We Debating a False Duality?

Gastrointestinal Oncology

The Best Approach to Esophagectomy: Do We Know Yet?